1|Page
ADVANCED PHARMACOLOGY FINAL EXAM (UTA)
Exam 2026-2027 BANK QUESTIONS WITH DETAILED
VERIFIED ANSWERS EXAM QUESTIONS WILL
COME FROM HERE (100% Latest Already Graded A+
Question 1
A 65-year-old patient with heart failure is prescribed digoxin. The nurse
practitioner understands that which of the following physiologic
changes associated with aging most significantly affects the
pharmacokinetics of this medication?
A. Increased glomerular filtration rate
B. Decreased hepatic blood flow
C. Reduced lean body mass
D. Increased gastric pH
Correct Answer: B
Explanation: Digoxin is primarily eliminated by the kidneys, but aging is
associated with decreased hepatic blood flow, which affects the
metabolism of drugs that undergo significant first-pass metabolism.
More importantly, digoxin is not extensively metabolized by the liver;
however, the key pharmacokinetic change in elderly patients is
decreased renal function, not increased gastric pH or reduced lean body
mass. Among the options provided, decreased hepatic blood flow is the
most significant age-related change affecting drug metabolism, though
,2|Page
the primary concern with digoxin is renal clearance. Reduced lean body
mass affects volume of distribution for lipid-soluble drugs, and
increased gastric pH affects absorption of weak acids and bases. The
most clinically significant age-related change for digoxin is decreased
renal clearance, but since that option is not provided, decreased hepatic
blood flow is the best answer as it reflects the broader physiologic
changes affecting drug disposition.
Question 2
A drug has a half-life of 12 hours and is administered intravenously
every 12 hours. Approximately how many hours will it take to reach
steady-state concentration?
A. 24 hours
B. 48 hours
C. 60 hours
D. 72 hours
Correct Answer: C
Explanation: Steady-state concentration is achieved after approximately
4 to 5 half-lives of drug administration. With a half-life of 12 hours, four
half-lives equal 48 hours, and five half-lives equal 60 hours. Therefore,
steady-state is typically reached between 48 and 60 hours after starting
the medication. The most accurate answer among the options is 60
hours, as this represents five half-lives, which is the standard clinical
approximation for achieving greater than 95% of steady-state
concentration. Twenty-four hours represents only two half-lives, which
would achieve only 75% of steady-state. Forty-eight hours represents
four half-lives, achieving approximately 94% of steady-state, but five
,3|Page
half-lives is the conventional threshold. Seventy-two hours would
represent six half-lives, which exceeds the standard requirement.
Question 3
A patient with renal impairment is prescribed a medication that is
primarily excreted unchanged in the urine. Which pharmacokinetic
parameter is most significantly altered in this patient?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Protein binding
Correct Answer: C
Explanation: Clearance is the parameter that directly reflects the
efficiency of drug elimination from the body. In patients with renal
impairment, the clearance of drugs that are primarily excreted by the
kidneys is significantly reduced, leading to drug accumulation and
increased risk of toxicity. Volume of distribution may be altered in renal
failure due to fluid shifts and changes in protein binding, but the most
direct and clinically significant pharmacokinetic change is reduced
clearance. Bioavailability is primarily affected by first-pass metabolism
and gastrointestinal absorption, which are not directly related to renal
function. Protein binding can be altered in renal failure due to
hypoalbuminemia or accumulation of endogenous substances that
displace drugs from binding sites, but clearance remains the parameter
most directly tied to renal excretory function. The nurse practitioner
must adjust dosing intervals or reduce the dose to prevent drug toxicity
when clearance is impaired.
, 4|Page
Question 4
A drug with high first-pass metabolism is administered orally. The nurse
practitioner anticipates that the bioavailability of this drug will be:
A. Greater than 90 percent
B. Significantly reduced compared to intravenous administration
C. Equivalent to intravenous administration
D. Increased in patients with liver disease
Correct Answer: B
Explanation: First-pass metabolism refers to the extensive metabolism
of a drug by the liver before it reaches the systemic circulation following
oral administration. Drugs with high first-pass metabolism have
significantly reduced bioavailability when taken orally because a large
portion of the absorbed drug is metabolized in the intestinal wall and
liver before entering the systemic circulation. This is why such drugs are
often administered via alternative routes such as intravenous,
sublingual, or transdermal to bypass the hepatic first-pass effect.
Bioavailability is defined as the fraction of the administered dose that
reaches the systemic circulation unchanged. For drugs with high first-
pass metabolism, this fraction is substantially less than the intravenous
dose, which by definition has 100% bioavailability. In patients with liver
disease, first-pass metabolism is actually reduced due to decreased
hepatic enzyme activity and reduced hepatic blood flow, leading to
increased bioavailability, not decreased. Therefore, the correct answer
is that bioavailability will be significantly reduced compared to
intravenous administration.
ADVANCED PHARMACOLOGY FINAL EXAM (UTA)
Exam 2026-2027 BANK QUESTIONS WITH DETAILED
VERIFIED ANSWERS EXAM QUESTIONS WILL
COME FROM HERE (100% Latest Already Graded A+
Question 1
A 65-year-old patient with heart failure is prescribed digoxin. The nurse
practitioner understands that which of the following physiologic
changes associated with aging most significantly affects the
pharmacokinetics of this medication?
A. Increased glomerular filtration rate
B. Decreased hepatic blood flow
C. Reduced lean body mass
D. Increased gastric pH
Correct Answer: B
Explanation: Digoxin is primarily eliminated by the kidneys, but aging is
associated with decreased hepatic blood flow, which affects the
metabolism of drugs that undergo significant first-pass metabolism.
More importantly, digoxin is not extensively metabolized by the liver;
however, the key pharmacokinetic change in elderly patients is
decreased renal function, not increased gastric pH or reduced lean body
mass. Among the options provided, decreased hepatic blood flow is the
most significant age-related change affecting drug metabolism, though
,2|Page
the primary concern with digoxin is renal clearance. Reduced lean body
mass affects volume of distribution for lipid-soluble drugs, and
increased gastric pH affects absorption of weak acids and bases. The
most clinically significant age-related change for digoxin is decreased
renal clearance, but since that option is not provided, decreased hepatic
blood flow is the best answer as it reflects the broader physiologic
changes affecting drug disposition.
Question 2
A drug has a half-life of 12 hours and is administered intravenously
every 12 hours. Approximately how many hours will it take to reach
steady-state concentration?
A. 24 hours
B. 48 hours
C. 60 hours
D. 72 hours
Correct Answer: C
Explanation: Steady-state concentration is achieved after approximately
4 to 5 half-lives of drug administration. With a half-life of 12 hours, four
half-lives equal 48 hours, and five half-lives equal 60 hours. Therefore,
steady-state is typically reached between 48 and 60 hours after starting
the medication. The most accurate answer among the options is 60
hours, as this represents five half-lives, which is the standard clinical
approximation for achieving greater than 95% of steady-state
concentration. Twenty-four hours represents only two half-lives, which
would achieve only 75% of steady-state. Forty-eight hours represents
four half-lives, achieving approximately 94% of steady-state, but five
,3|Page
half-lives is the conventional threshold. Seventy-two hours would
represent six half-lives, which exceeds the standard requirement.
Question 3
A patient with renal impairment is prescribed a medication that is
primarily excreted unchanged in the urine. Which pharmacokinetic
parameter is most significantly altered in this patient?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Protein binding
Correct Answer: C
Explanation: Clearance is the parameter that directly reflects the
efficiency of drug elimination from the body. In patients with renal
impairment, the clearance of drugs that are primarily excreted by the
kidneys is significantly reduced, leading to drug accumulation and
increased risk of toxicity. Volume of distribution may be altered in renal
failure due to fluid shifts and changes in protein binding, but the most
direct and clinically significant pharmacokinetic change is reduced
clearance. Bioavailability is primarily affected by first-pass metabolism
and gastrointestinal absorption, which are not directly related to renal
function. Protein binding can be altered in renal failure due to
hypoalbuminemia or accumulation of endogenous substances that
displace drugs from binding sites, but clearance remains the parameter
most directly tied to renal excretory function. The nurse practitioner
must adjust dosing intervals or reduce the dose to prevent drug toxicity
when clearance is impaired.
, 4|Page
Question 4
A drug with high first-pass metabolism is administered orally. The nurse
practitioner anticipates that the bioavailability of this drug will be:
A. Greater than 90 percent
B. Significantly reduced compared to intravenous administration
C. Equivalent to intravenous administration
D. Increased in patients with liver disease
Correct Answer: B
Explanation: First-pass metabolism refers to the extensive metabolism
of a drug by the liver before it reaches the systemic circulation following
oral administration. Drugs with high first-pass metabolism have
significantly reduced bioavailability when taken orally because a large
portion of the absorbed drug is metabolized in the intestinal wall and
liver before entering the systemic circulation. This is why such drugs are
often administered via alternative routes such as intravenous,
sublingual, or transdermal to bypass the hepatic first-pass effect.
Bioavailability is defined as the fraction of the administered dose that
reaches the systemic circulation unchanged. For drugs with high first-
pass metabolism, this fraction is substantially less than the intravenous
dose, which by definition has 100% bioavailability. In patients with liver
disease, first-pass metabolism is actually reduced due to decreased
hepatic enzyme activity and reduced hepatic blood flow, leading to
increased bioavailability, not decreased. Therefore, the correct answer
is that bioavailability will be significantly reduced compared to
intravenous administration.
